LDS/Medical Tests/Post-transplant Rejection Assessment, Kidney, Heart, Lung (Prospera™, AlloSure®, VitaGraft™/GraftAssureDx)

Post-transplant Rejection Assessment, Kidney, Heart, Lung (Prospera™, AlloSure®, VitaGraft™/GraftAssureDx)

End-stage organ disease often requires transplantation, yet long-term graft survival remains limited due to the risk of acute and chronic rejection. In the United States alone, over 20,000 patients undergo kidney transplantation annually, with more than 200,000 living with a functioning graft. Despite advances in immunosuppressive therapy, approximately 20–30% of kidney transplant recipients experience rejection within the first 5 years, and only about 55% of kidney grafts survive at 10 years. Traditional tools such as serum creatinine or allograft biopsy have significant limitations. Serum creatinine lacks sensitivity and specificity, while biopsies are invasive and often detect rejection only after substantial organ injury has occurred.

The Prospera™ test (Natera®) is a noninvasive, blood-based assay that measures donor-derived cell-free DNA (dd-cfDNA) using next-generation sequencing (NGS). The assay analyzes 13,962 SNPs selected for maximum informativeness to quantify dd-cfDNA in transplant recipients. Elevated levels of dd-cfDNA signal graft injury and increased risk of rejection. Clinical studies have shown that dd-cfDNA levels rise months before clinical or histologic evidence of rejection, enabling earlier detection. Published data reports a sensitivity of 83% and specificity of 81% for detecting active rejection. In addition to kidney transplantation, Prospera™ has been validated for heart and lung transplant recipients, supporting its role as a broad organ health monitoring tool. This enables clinicians to optimize immunosuppressive management, reduce unnecessary biopsies, and intervene earlier to protect graft function.

AlloSure‐Heart® is a non‐invasive blood test that assesses organ health by directly measuring allograft injury. AlloSure‐Heart® helps to assess for acute rejection, potentially enabling better management of heart transplant recipients. The AlloSure‐Heart® test measures donor‐derived cell‐free DNA (dd‐cfDNA) in heart transplant recipients. Cell‐free DNA is present in plasma as a product of cell injury and death. dd‐cfDNA is fragments of DNA in the recipient’s bloodstream that originate from cells from the donated organ and therefore are of the donor genotype and indicate specifically the level of graft cell injury and death.

GraftAssureDx is designed to measure both relative (percentage) and absolute (copies per mL) levels of donor-derived cell-free DNA (dd-cfDNA) in plasma after kidney transplantation, helping clinicians assess the probability of allograft rejection at the time of testing in conjunction with standard clinical evaluations. The assay currently remains under evaluation and has not yet been reviewed by the U.S. Food and Drug Administration; its safety and efficacy are still being investigated in clinical trials.

  • Predicts the risk of acute and chronic rejection in kidney, heart, and lung transplant recipients
  • Guides optimization of immunosuppressive regimens in a personalized manner
  • Improves long-term graft survival through earlier detection of rejection

Percentage of dd-cfDNA and the absolute quantity present in the sample is reported.

Increased risk for rejection:

  • dd-cfDNA >=1% or dd-cfDNA >=78 cp/mL

Decreased risk for rejection:

  • dd-cfDNA <1% or dd-cfDNA <78 cp/mL

dd-cfDNA <1% dd-cfDNA <78 cp/mL

Liquid biopsy with Next-generation sequencing (NGS).

Whole blood, EDTA.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: 30 days
Serum creatinine, Albumin creatinine ratio, urinalysis, microalbumin, CBC, kidney biopsy, HLA class I and II genotyping, Tuteva post-transplant test for kidney acute rejection.
7-10 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login